Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | SPR | P35270 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156435 | 0.84 | NAMPT (0.47) | NAMPTNR1H2PDK2SPRMAPT | |
| SCHEMBL17317692 | 0.84 | NAMPT (0.47) | NAMPTNR1H2SPRMAPTMAPK1 | |
| SCHEMBL14970393 | 0.84 | NOTUM (0.48) | NAMPTNR1H2PDK2SPRCCNA2 | |
| SCHEMBL29573372 | 0.84 | NAMPT (0.40) | NAMPTNR1H2PDK2SPRPSEN1 | |
| SCHEMBL31613473 | 0.80 | NAMPT (0.46) | NAMPTNR1H2PDK2SPR | |
| SCHEMBL16219017 | 0.80 | AURKA (0.40) | NAMPTNR1H2PDK2SPRPSEN1 | |
| SCHEMBL19722672 | 0.80 | NAMPT (0.41) | NAMPTNR1H2PDK2SPRPSEN1 | |
| SCHEMBL6890800 | 0.76 | NR1H2 (0.62) | NAMPTNR1H2PDK2PSEN1PSEN2 | |
| SCHEMBL20557798 | 0.73 | CCNA2 (0.36) | CCNA2CDK2CCNA1 | |
| SCHEMBL25252226 | 0.73 | NAMPT (0.46) | NAMPTSPRCCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4507566-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Belite Bio, Inc (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-113557017-B | Inhibitors of cyclin-dependent kinase 7 and uses thereof | 丹娜-法伯癌症研究院 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20220185813-A1 | MODULATORS OF AMPA RECEPTOR SIGNALING | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2022-06-16 | — | — | US | disclosed |
| CN-113166144-A | Aryl compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-2571876-B1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9181262-B2 | Crystalline forms of a dipeptidyl peptidase-IV inhibitors | MERCK SHARP & DOHME CORP (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099891-A1 | NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
| US-8980929-B2 | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8895603-B2 | Crystalline forms of a dipeptidyl peptidase-IV inhibitor | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2473047-B1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140080884-A1 | NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK SHARP & DOHME LTD. (GB) | 2014-03-20 | — | — | US | disclosed |
| US-8653059-B2 | Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130203786-A1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2013-08-08 | — | — | US | disclosed |
| US-8455533-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120149734-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-20110224195-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| EP-2190428-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009025784-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149734-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | NAMPT 801/4885NR1H2 3087/4885PDK2 1271/4885 |
| US-20150099891-A1 | NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | NAMPT 1184/4885NR1H2 4497/4885PDK2 1292/4885 |
| US-20140080884-A1 | NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | DPP4, DPP3, DPP7 | NAMPT 1209/4885NR1H2 4506/4885PDK2 1318/4885 |
| US-20220185813-A1 | MODULATORS OF AMPA RECEPTOR SIGNALING | GRM2, GRM1, GRIK2 | NAMPT 2441/4885NR1H2 162/4885PDK2 704/4885 |
| US-20130203786-A1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP7, DPP3 | NAMPT 939/4885NR1H2 3025/4885PDK2 661/4885 |
| US-20110224195-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | NAMPT 651/4885NR1H2 2047/4885PDK2 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.